Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 13Terminated 4Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Gastric Adenocarcinoma 1Erectile Dysfunction 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Tadalafil × Clear all
NCT05709574 2025-10-16

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

University of Arizona

Phase 2 Recruiting
10 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT06717711 2024-12-05

RCT_LiESWT

Regina Elena Cancer Institute

Phase 3 Recruiting
158 enrolled
Genitourinary

Prostatic Neoplasms, Urogenital Neoplasms

NCT05558007 2024-10-22

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Biozeus Biopharmaceutical S.A.

Phase 2 Recruiting
72 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡